Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.

By T. Baglin, R. Luddington, K. Brown, C. Baglin. The Lancet, 2003

725 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. (2020, background): “This risk has been estimated to be as high as 10% by 1 year and up to 30% by 5 to 10 years.(10,11,313) The ASH guideline panel has provided a conditional recommendation for continuing antithrombotic therapy indefinitely after completion of primary treatment for patients with unprovoked VTE, based on”
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, methodology): “For patients with first PE/VTE secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months.(331,340,341) I B”
Thrombophilia, clinical factors, and recurrent venous thrombotic events. (2005, neutral): “Incidence rate (95% CI)† 29 (13-58) 44 (32-58) 15 (10-24) 17 (9-29)”